Fine Tuning for Quality of Life: 21st Century Approach to Treatment of Addison's Disease

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 2, 2009, Pages 407-418

  Reisch, Nicole ^a   Arlt, Wiebke ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Addison's disease; Adrenal insufficiency; Aldosterone; Cortisol; Dehydroepiandrosterone; Mortality; Quality of life

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; FLUDROCORTISONE; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; LEVOTHYROXINE; MITOTANE; PLACEBO; PRASTERONE; PREDNISOLONE; RIFAMPICIN; TESTOSTERONE;

ADDISON DISEASE; ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ANDROGEN DEFICIENCY; CHRONOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; CORTICOSTEROID THERAPY; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; DISABILITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG POTENCY; EMERGENCY CARE; EVENING DOSAGE; HORMONE SUBSTITUTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOPITUITARISM; LIBIDO DISORDER; MOOD DISORDER; MORNING DOSAGE; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SEPTIC SHOCK; SINGLE DRUG DOSE;

ADDISON DISEASE; HUMANS; QUALITY OF LIFE;

EID: 62749140741     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2009.01.008     Document Type: Review

References (47)

1. Addison T. On the constitutional and local effects of diseases of the supra-renal capsules (1855), Warrren and Son, London
2. Tomlinson J.W., Holden N., Hills R.K., et al. Association between premature mortality and hypopituitarism: West Midlands Prospective Hypopituitary Study Group. Lancet 357 9254 (2001) 425-431
3. Bergthorsdottir R., Leonsson-Zachrisson M., Oden A., et al. Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab 91 12 (2006) 4849-4853
4. Lovas K., Loge J.H., and Husebye E.S. Subjective health status in Norwegian patients with Addison's disease. Clin Endocrinol (Oxf) 56 5 (2002) 581-588
5. Hahner S., Loeffler M., Fassnacht M., et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 92 10 (2007) 3912-3922
6. Zelissen P.M., Bast E.J., and Croughs R.J. Associated autoimmunity in Addison's disease. J Autoimmun 8 1 (1995) 121-130
7. Zelissen P.M., Croughs R.J., van Rijk P.P., et al. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 120 3 (1994) 207-210
8. Arlt W., Callies F., van Vlijmen J.C., et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 341 14 (1999) 1013-1020
9. Gurnell E.M., Hunt P.J., Curran S.E., et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab 93 2 (2008) 400-409
10. Hunt P.J., Gurnell E.M., Huppert F.A., et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab 85 12 (2000) 4650-4656
11. Johannsson G., Burman P., Wiren L., et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 87 5 (2002) 2046-2052
12. Brooke A.M., Kalingag L.A., Miraki-Moud F., et al. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. J Clin Endocrinol Metab 91 10 (2006) 3773-3779
13. Miller K.K., Biller B.M., Beauregard C., et al. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 91 5 (2006) 1683-1690
14. Miller K.K., Biller B.M., Schaub A., et al. Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. J Clin Endocrinol Metab 92 7 (2007) 2474-2479
15. Esteban N.V., Loughlin T., Yergey A.L., et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 72 1 (1991) 39-45
16. Kerrigan J.R., Veldhuis J.D., Leyo S.A., et al. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab 76 6 (1993) 1505-1510
17. Charmandari E., Johnston A., Brook C.G., et al. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Endocrinol 169 1 (2001) 65-70
18. Mah P.M., Jenkins R.C., Rostami-Hodjegan A., et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 61 3 (2004) 367-375
19. Arlt W., and Allolio B. Adrenal insufficiency. Lancet 361 9372 (2003) 1881-1893
20. Groves R.W., Toms G.C., Houghton B.J., et al. Corticosteroid replacement therapy: twice or thrice daily?. J R Soc Med 81 9 (1988) 514-516
21. Riedel M., Wiese A., Schurmeyer T.H., et al. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. Exp Clin Endocrinol 101 2 (1993) 106-111
22. Braatvedt G.D., Joyce M., Evans M., et al. Bone mineral density in patients with treated Addison's disease. Osteoporos Int 10 6 (1999) 435-440
23. Arlt W., Rosenthal C., Hahner S., et al. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf) 64 4 (2006) 384-389
24. Allolio B., Winkelmann W., Fricke U., et al. [Cortisol plasma concentration in patients with primary adrenal cortex insufficiency during substitution therapy with cortisone acetate]. Verh Dtsch Ges Inn Med 84 (1978) 1456-1458
25. Feek C.M., Ratcliffe J.G., Seth J., et al. Patterns of plasma cortisol and ACTH concentrations in patients with Addison's disease treated with conventional corticosteroid replacement. Clin Endocrinol (Oxf) 14 5 (1981) 451-458
26. Scott R.S., Donald R.A., and Espiner E.A. Plasma ACTH and cortisol profiles in Addisonian patients receiving conventional substitution therapy. Clin Endocrinol (Oxf) 9 6 (1978) 571-576
27. Allolio B., Kaulen D.U.D., Hipp F.X., et al. Comparison between hydrocortisone and cortisone acetate as replacement therapy in adrenocortical insufficiency. Akt Endokr Stoffw 6 (1985) 35-39
28. Burch W.M. Urine free-cortisol determination: a useful tool in the management of chronic hypoadrenal states. JAMA 247 14 (1982) 2002-2004
29. Howlett T.A. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 46 3 (1997) 263-268
30. Oelkers W., Diederich S., and Bahr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab 75 1 (1992) 259-264
31. Hahner S., Löffler M., Bleicken B., et al. Adrenal crisis in primary and secondary adrenal insufficiency: frequency and causes. Endocrine Abstracts 16 (2008) 55
32. White K., Wass J., Elliott A., et al. Adrenal emergency is a regular event for treated Addison's patients. Endocrine Abstracts 15 (2008) 308
33. Flemming T.G., and Kristensen L.O. Quality of self-care in patients on replacement therapy with hydrocortisone. J Intern Med 246 5 (1999) 497-501
34. Nicholas J.A., Burstein C.L., Umberger C.J., et al. Management of adrenocortical insufficiency during surgery. AMA Arch Surg 71 5 (1955) 737-742
35. Plumpton F.S., and Besser G.M. The adrenocortical response to surgery and insulin-induced hypoglycaemia in corticosteroid-treated and normal subjects. Br J Surg 56 3 (1969) 216-219
36. Arlt W., Hammer F., Sanning P., et al. Dissociation of serum dehydroepiandrosterone and dehydroepiandrosterone sulfate in septic shock. J Clin Endocrinol Metab 91 7 (2006) 2548-2554
37. Oppert M., Reinicke A., Graf K.J., et al. Plasma cortisol levels before and during "low-dose" hydrocortisone therapy and their relationship to hemodynamic improvement in patients with septic shock. Intensive Care Med 26 12 (2000) 1747-1755
38. Thomsen A.F., Kvist T.K., Andersen P.K., et al. The risk of affective disorders in patients with adrenocortical insufficiency. Psychoneuroendocrinology 31 5 (2006) 614-622
39. Miller K.K., Biller B.M., Hier J., et al. Androgens and bone density in women with hypopituitarism. J Clin Endocrinol Metab 87 6 (2002) 2770-2776
40. Arlt W. Androgen therapy in women. Eur J Endocrinol 154 1 (2006) 1-11
41. Coles A.J., Thompson S., Cox A.L., et al. Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4 + CD25hi and CD4 + FoxP3+) T cells. Eur J Immunol 35 12 (2005) 3694-3703
42. Parasrampuria J., Schwartz K., and Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. JAMA 280 18 (1998) 1565
43. Plat L., Leproult R., L'Hermite-Baleriaux M., et al. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab 84 9 (1999) 3082-3092
44. Lovas K., Husebye E.S., Holsten F., et al. Sleep disturbances in patients with Addison's disease. Eur J Endocrinol 148 4 (2003) 449-456
45. Merza Z., Rostami-Hodjegan A., Memmott A., et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 65 1 (2006) 45-50
46. Lovas K., and Husebye E.S. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol 157 1 (2007) 109-112
47. Newell-Price J., Whiteman M., Rostami-Hodjegan A., et al. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) 68 1 (2008) 130-135